Parallel Advisors’s Quince Therapeutics QNCX Stock Holding History

Parallel Advisors’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$81	Buy	4 +3	+300%	+$602	﹤0.01%	3789
2025 Q4	$988	Hold	1	–	–	﹤0.01%	3299
2025 Q3	$481	Hold	1	–	–	﹤0.01%	3337
2025 Q2	$487	Hold	1	–	–	﹤0.01%	3307
2025 Q1	$392	Hold	1	–	–	﹤0.01%	3276
2024 Q4	$552	Hold	1	–	–	﹤0.01%	3208
2024 Q3	$229	Hold	1	–	–	﹤0.01%	3291
2024 Q2	$221	Sell	1 -1	-50%	-$181	﹤0.01%	3193
2024 Q1	$330	Sell	2 -10	-83%	-$2.48K	﹤0.01%	3101
2023 Q4	$2.5K	Hold	12	–	–	﹤0.01%	2735
2023 Q3	$2.66K	Hold	12	–	–	﹤0.01%	2727
2023 Q2	$3.58K	Hold	12	–	–	﹤0.01%	2551
2023 Q1	$3.71K	Hold	12	–	–	﹤0.01%	2527
2022 Q4	$1.56K	Hold	12	–	–	﹤0.01%	2777
2022 Q3	$3K	Hold	12	–	–	﹤0.01%	2521
2022 Q2	$5K	Buy	12 +4	+50%	+$2.83K	﹤0.01%	2280
2022 Q1	$10K	Hold	8	–	–	﹤0.01%	2035
2021 Q4	$21K	Sell	8 -3	-27%	-$18.3K	﹤0.01%	1756
2021 Q3	$196K	Buy	11 +5	+83%	+$79.5K	0.01%	726
2021 Q2	$66K	Buy	6 +1	+20%	+$8.38K	﹤0.01%	1109
2021 Q1	$34K	Hold	5	–	–	﹤0.01%	1352
2020 Q4	$26K	Hold	5	–	–	﹤0.01%	1377
2020 Q3	$47K	Hold	5	–	–	﹤0.01%	1091
2020 Q2	$43K	Hold	5	–	–	﹤0.01%	1109
2020 Q1	$43K	Buy	+5	New	+$49.4K	﹤0.01%	1006

Other funds holding QNCX

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Parallel Advisors's QNCX Position: Q1 2026 in Review

Parallel Advisors increased its Quince Therapeutics (QNCX) stake by 300% in Q1 2026, buying an estimated $602 and bringing the position to 4 shares worth $81. The position accounts for ﹤0.01% of the portfolio, ranked #3789.

Parallel Advisors first reported a position in QNCX in Q1 2020 and has held it in 25 quarters since. The position peaked at $196K in Q3 2021. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

Parallel Advisors held 4 shares of Quince Therapeutics worth $81 as of Q1 2026.
Parallel Advisors bought 3 Quince Therapeutics shares in Q1 2026, an estimated $602.
Quince Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3789 holding.
Parallel Advisors first reported a position in Quince Therapeutics in Q1 2020 and has held it in 25 quarters since.
Parallel Advisors's Quince Therapeutics position peaked at $196K in Q3 2021.
43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.